image credit: Unsplash

Avectas, CCRM Enter Cell Therapy Tie-up

Avectas, a cell engineering technology business, and CCRM, a leader in developing and commercializing cell and gene therapies, have entered into a collaboration to accelerate the translation of Avectas’ non-viral cell engineering platform (Solupore) into the clinic.

Cell and gene therapies offer the potential to dramatically transform the treatment of diseases, including cancer, for millions of patients worldwide. However, a global viral vector shortfall could halt progress in the industry as very few contract development and manufacturing organizations (CDMOs) have the capabilities required to manufacture vectors that can deliver molecules to cells.

Read More on Contract Pharma